Literature DB >> 25172336

Immunofluorescent assay of ERCC1 and estimation of clinical significance of the protein expression in ovarian cancer tissue.

T A Bogush1, E A Dudko, A V Semakov, E A Bogush, A S Tjulandina, V T Zarkua, S A Tjulandin, M I Davydov.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25172336     DOI： 10.1134/S1607672914040073

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN： 1607-6729            Impact factor:   0.788


× No keyword cloud information.
  8 in total

1.  ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.

Authors:  Mustafa Zelal Muallem; Ioana Braicu; Mani Nassir; Rolf Richter; Jalid Sehouli; Ruza Arsenic
Journal:  Anticancer Res       Date:  2014-01       Impact factor: 2.480

Review 2.  [Discordance of estrogen receptor status between primary and metastatic breast cancer--possible reasons and prognostic value].

Authors:  T A Bogush; A S Popova; E A Dudko; E O Ignatova; B E Polotskiĭ; S A Tiuliandin; M I Davydov
Journal:  Antibiot Khimioter       Date:  2013

Review 3.  Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy.

Authors:  Hiroshi Okumura; Yasuto Uchikado; Tetsuro Setoyama; Masataka Matsumoto; Tetsuhiro Owaki; Sumiya Ishigami; Shoji Natsugoe
Journal:  Surg Today       Date:  2013-04-19       Impact factor: 2.549

4.  Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy.

Authors:  Hans Bösmüller; Sophie Haitchi-Petnehazy; Gerald Webersinke; Renate Marschon; Franz Roithmeier; Wolfgang Stummvoll; Tanja Fehm; Margit Klier-Richter; Irina Bonzheim; Annette Staebler; Falko Fend
Journal:  Virchows Arch       Date:  2011-06-29       Impact factor: 4.064

5.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Authors:  Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2006-09-07       Impact factor: 91.245

6.  Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer.

Authors:  Feng-Ying Li; Xiao-Bin Ren; Xin-You Xie; Jun Zhang
Journal:  Asian Pac J Cancer Prev       Date:  2013

7.  Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer.

Authors:  Jan Nyrop Jakobsen; Eric Santoni-Rugiu; Jesper Ravn; Jens Benn Sørensen
Journal:  Eur J Cancer       Date:  2013-04-29       Impact factor: 9.162

8.  Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.

Authors:  S W Johnson; P A Swiggard; L M Handel; J M Brennan; A K Godwin; R F Ozols; T C Hamilton
Journal:  Cancer Res       Date:  1994-11-15       Impact factor: 12.701
  8 in total
  1 in total

1.  Urinary interleukin-1β levels among gynecological patients.

Authors:  Kamisha T Woolery; Mitchel S Hoffman; Joshua Kraft; Santo V Nicosia; Ambuj Kumar; Patricia A Kruk
Journal:  J Ovarian Res       Date:  2014-11-18       Impact factor: 4.234
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.